Puma Biotechnology
PBYI
115 hedge funds and large institutions have $226M invested in Puma Biotechnology in 2021 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 51 increasing their positions, 35 reducing their positions, and 16 closing their positions.
99% more call options, than puts
Call options by funds: $878K | Put options by funds: $441K
46% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 35
4% less funds holding
Funds holding: 120 → 115 (-5)
7.25% less ownership
Funds ownership: 86.13% → 78.88% (-7.3%)
29% less capital invested
Capital invested by funds: $319M → $226M (-$93.1M)
31% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$7.56M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$5.24M |
| 3 |
Goldman Sachs
New York
|
+$3.16M |
| 4 |
EP
Eversept Partners
New York
|
+$2.98M |
| 5 |
Russell Investments Group
London,
United Kingdom
|
+$2.61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$34.6M |
| 2 |
State Street
Boston,
Massachusetts
|
-$6.68M |
| 3 |
JAM
Jupiter Asset Management
London,
United Kingdom
|
-$5.92M |
| 4 |
FAM
Fred Alger Management
New York
|
-$3.86M |
| 5 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$1.87M |
PBYI Hedge Fund Activity: Q3 2021 in Review
115 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Puma Biotechnology (PBYI) for Q3 2021, worth a combined $226M — down 29% from $319M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of PBYI and 11 opened new positions — a net loss of 5 holders — while 35 trimmed existing stakes and 51 added.
The largest buyer was Millennium Management, adding an estimated $7.56M. The largest seller was Deerfield Management, exiting entirely with an estimated $34.6M sold.
- 115 institutional investors held Puma Biotechnology (PBYI) as of Q3 2021, down from 120 in Q2 2021.
- Funds reported $226M of Puma Biotechnology stock for Q3 2021, down 29% quarter-over-quarter.
- 11 funds opened new Puma Biotechnology positions in Q3 2021 and 16 closed out, a net change of -5 holders.
- The largest Puma Biotechnology buyer in Q3 2021 was Millennium Management, an estimated $7.56M added.
- The largest Puma Biotechnology seller in Q3 2021 was Deerfield Management, an estimated $34.6M sold.
Based on aggregated 13F filings for Q3 2021.